Annette M. Molinaro

ORCID: 0000-0002-9854-7404
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Epigenetics and DNA Methylation
  • Radiomics and Machine Learning in Medical Imaging
  • Bladder and Urothelial Cancer Treatments
  • Meningioma and schwannoma management
  • Brain Metastases and Treatment
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Neuroblastoma Research and Treatments
  • MRI in cancer diagnosis
  • Immune cells in cancer
  • Cancer, Hypoxia, and Metabolism
  • Ferroptosis and cancer prognosis
  • Statistical Methods and Inference
  • ATP Synthase and ATPases Research
  • Chemokine receptors and signaling
  • Pancreatic and Hepatic Oncology Research
  • Immunotherapy and Immune Responses
  • MicroRNA in disease regulation
  • Gene expression and cancer classification
  • Cancer Mechanisms and Therapy
  • Cutaneous Melanoma Detection and Management
  • Advanced MRI Techniques and Applications
  • Nonmelanoma Skin Cancer Studies
  • Cancer Research and Treatments

Neurological Surgery
2016-2025

University of California, San Francisco
2016-2025

University of California, Berkeley
2003-2025

Azienda Ospedaliero-Universitaria di Modena
2024

University of San Francisco
2014-2024

Universidade São Francisco
2024

Immatics Biotechnologies (Germany)
2023

City College of San Francisco
2014-2023

University of Illinois Urbana-Champaign
2023

Christ University
2023

In genomic studies, thousands of features are collected on relatively few samples. One the goals these studies is to build classifiers predict outcome future observations. There three inherent steps this process: feature selection, model selection and prediction assessment. With a focus assessment, we compare several methods for estimating 'true' error in presence selection.For small where selected from candidates, resubstitution simple split-sample estimates seriously biased. samples,...

10.1093/bioinformatics/bti499 article EN Bioinformatics 2005-05-19

The colony stimulating factor 1 receptor (CSF1R) ligands, CSF1 and interleukin-34, the KIT ligand, stem cell factor, are expressed in glioblastoma (GB). Microglia, macrophages, blood vessels, tumor cells also express CSF1R, depletion of microglia reduces burden invasive capacity. PLX3397 is an oral, small molecule that selectively inhibits CSF1R KIT, penetrates blood–brain barrier model systems, represents a novel approach for clinical development. We conducted phase II study patients with...

10.1093/neuonc/nov245 article EN Neuro-Oncology 2015-10-08

Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH)-wild-type and IDH-mutant subtypes, with median patient survival of 1.2 3.6 years, respectively. Although maximal resection contrast-enhanced (CE) tumor is associated longer survival, prognostic importance within molecular subgroups potential non-contrast-enhanced (NCE) disease poorly understood.To assess association CE NCE tumors in...

10.1001/jamaoncol.2019.6143 article EN JAMA Oncology 2020-02-06

Antiangiogenic therapy leads to devascularization that limits tumor growth. However, the benefits of angiogenesis inhibitors are typically transient and resistance often develops. In this study, we explored hypothesis hypoxia caused by antiangiogenic induces cell autophagy as a cytoprotective adaptive response, thereby promoting treatment resistance. Hypoxia-induced was dependent on signaling through hypoxia-inducible factor-1α (HIF-1α)/AMPK pathway, hypoxic cells with shift from autophagic...

10.1158/0008-5472.can-11-3831 article EN Cancer Research 2012-03-24
Floris P Barthel Kevin C. Johnson Frederick S. Varn Anzhela D. Moskalik Georgette Tanner and 95 more Emre Kocakavuk Kevin Anderson Olajide Abiola Kenneth Aldape Kristin Alfaro-Munoz Donát Alpár Samirkumar B. Amin David M. Ashley Pratiti Bandopadhayay Jill S. Barnholtz‐Sloan Rameen Beroukhim Christoph Bock Priscilla K. Brastianos Daniel J. Brat Andrew Brodbelt Alexander Bruns Ketan R. Bulsara Aruna Chakrabarty Arnab Chakravarti Jeffrey H. Chuang Elizabeth B. Claus Elizabeth J. Cochran Jennifer Connelly J Costello Gaetano Finocchiaro Michael Fletcher Pim J. French Hui Gan Mark R. Gilbert Peter V. Gould Matthew Grimmer Antonio Iavarone Azzam Ismail Michael D. Jenkinson Mustafa Khasraw Hoon Kim Mathilde C.M. Kouwenhoven Peter S. LaViolette Ho‐Keung Ng Peter Lichter Keith L. Ligon Allison Lowman Tathiane M. Malta Tali Mazor Kerrie L. McDonald Annette M. Molinaro Do‐Hyun Nam Naema Nayyar Ho‐Keung Ng Chew Yee Ngan Simone P. Niclou Johanna M. Niers Houtan Noushmehr Javad Noorbakhsh D. Ryan Ormond Chul‐Kee Park Laila Poisson Raúl Rabadán Bernhard Radlwimmer Hui Gan Guido Reifenberger K. Jason Michael Schuster Brian Shaw Susan Short Peter A. Sillevis Smitt Andrew E. Sloan Marion Smits Hiromichi Suzuki Ghazaleh Tabatabai Erwin G. Van Meir Colin Watts Michael Weller Pieter Wesseling Bart A. Westerman Georg Widhalm Adelheid Wöehrer W. K. Alfred Yung Gelareh Zadeh Jason T. Huse John de Groot Lucy F. Stead Roel G.W. Verhaak Floris P Barthel Kevin C. Johnson Frederick S. Varn Anzhela D. Moskalik Georgette Tanner Emre Kocakavuk Kevin Anderson Kenneth Aldape Kristin Alfaro-Munoz Samirkumar B. Amin David M. Ashley Pratiti Bandopadhayay

10.1038/s41586-019-1775-1 article EN Nature 2019-11-20

Awake craniotomy is currently a useful surgical approach to help identify and preserve functional areas during cortical subcortical tumor resections. Methodologies have evolved over time maximize patient safety minimize morbidity using this technique. The goal of study analyze single surgeon's experience the evolving methodology awake language sensorimotor mapping for glioma surgery.The authors retrospectively studied patients undergoing brain surgery between 1986 2014. Operations initial...

10.3171/2014.10.jns141520 article EN Journal of neurosurgery 2015-04-24

Significant gaps exist in our understanding of the causes and clinical management glioma. One biggest is how best to manage low-grade (World Health Organization [WHO] Grade II) Low-grade glioma (LGG) a uniformly fatal disease young adults (mean age 41 years), with survival averaging approximately 7 years. Although LGG patients have better than high-grade (WHO III or IV) glioma, all LGGs eventually progress death. Data from Surveillance, Epidemiology End Results (SEER) program National Cancer...

10.3171/2014.10.focus12367 article EN Neurosurgical FOCUS 2015-01-01

BackgroundStudies have failed to identify characteristics of women who been diagnosed with ductal carcinoma in situ (DCIS) and a high or low risk subsequent invasive cancer.

10.1093/jnci/djq101 article EN JNCI Journal of the National Cancer Institute 2010-04-28

The authors sought to determine the incidence, time course, and risk factors for overall adverse radiation effect (ARE) symptomatic ARE after stereotactic radiosurgery (SRS) brain metastases.All cases of metastases treated from 1998 through 2009 with Gamma Knife SRS at UCSF were considered. Cases less than 3 months follow-up imaging, a gap more 8 in imaging during 1st year, or inadequate availability excluded. Brain scans pathology reports reviewed ensure consistent scoring dates ARE,...

10.3171/2014.10.jns141610 article EN Journal of neurosurgery 2015-05-15

VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab recurrent glioblastoma.Eighty bevacizumab-naïve patients were randomized (cohort A, n = 50) monotherapy B, 30). The primary endpoint was 6-month progression-free survival (PFS-6). Assessed biomarkers included evaluation tumor programmed death-ligand 1 expression, tumor-infiltrating lymphocyte density, immune activation gene expression...

10.1158/1078-0432.ccr-20-2500 article EN Clinical Cancer Research 2020-11-16

Terminology to describe extent of resection in glioblastoma is inconsistent across clinical trials. A surgical classification system was previously proposed based upon residual contrast-enhancing (CE) tumor. We aimed (1) explore the prognostic utility and (2) define how much removed non-CE tumor translates into a survival benefit.The international RANO resect group retrospectively searched compiled databases from 7 neuro-oncological centers USA Europe for patients with newly diagnosed per...

10.1093/neuonc/noac193 article EN cc-by-nc Neuro-Oncology 2022-08-12

Abstract Gliomas synaptically integrate into neural circuits 1,2 . Previous research has demonstrated bidirectional interactions between neurons and glioma cells, with neuronal activity driving growth 1–4 gliomas increasing excitability 2,5–8 Here we sought to determine how glioma-induced changes influence underlying cognition whether these patient survival. Using intracranial brain recordings during lexical retrieval language tasks in awake humans together site-specific tumour tissue...

10.1038/s41586-023-06036-1 article EN cc-by Nature 2023-05-03

Abstract DNA methylation microarrays can be employed to interrogate cell-type composition in complex tissues. Here, we expand reference-based deconvolution of blood include 12 leukocyte subtypes (neutrophils, eosinophils, basophils, monocytes, naïve and memory B cells, CD4 + CD8 T natural killer, regulatory cells). Including derived variables, our method provides 56 immune profile variables. The IDOL (IDentifying Optimal Libraries) algorithm was used identify libraries for data current...

10.1038/s41467-021-27864-7 article EN cc-by Nature Communications 2022-02-09

PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade (RANO-LGG) were developed to improve reliability of response assessment glioma trials. Over time, some limitations these identified, challenges emerged regarding integrating features the modified RANO (mRANO) or immunotherapy (iRANO) criteria. METHODS Informed by data from studies evaluating different criteria, updates are proposed (RANO 2.0). RESULTS We recommend a standard set...

10.1200/jco.23.01059 article EN Journal of Clinical Oncology 2023-09-29

PURPOSE In patients with diffuse low-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part because randomized clinical trial different levels EOR is not feasible. METHODS 20-year retrospective cohort 392 IDH-mutant grade 2 glioma, we analyzed combined effects volumetric and molecular factors on overall survival (OS) progression-free by recursive partitioning analysis. The OS results were validated two external cohorts (n = 365). Propensity score...

10.1200/jco.21.02929 article EN Journal of Clinical Oncology 2023-01-04

Histopathologic evaluation of glioblastoma multiforme (GBM) at initial diagnosis is typically performed on tissue obtained from regions contrast enhancement (CE) as depicted gadolinium-enhanced, T1-weighted images. The non-enhancing (NE) portion the lesion, which contains both reactive edema and infiltrative tumor, only partially removed due to concerns about damaging functioning brain. purpose this study was evaluate histopathologic physiologic MRI features image-guided specimens CE NE...

10.1093/neuonc/nos128 article EN Neuro-Oncology 2012-06-18

DNA methylation is an important component of epigenetic modifications, which influences the transcriptional machinery aberrant in many human diseases. In this study we present first genome-wide integrative analysis promoter and gene expression for identification markers melanoma. Genome-wide eight early-passage melanoma cell strains were compared with newborn adult melanocytes. We used linear mixed effect models (LME) combination a series filters based on localization relative to...

10.1101/gr.091447.109 article EN cc-by-nc Genome Research 2009-06-02

Lower-grade (World Health Organization Grades II and III) gliomas vary widely in clinical behavior are classified as astrocytic, oligodendroglial, or mixed. Anaplasia depends greatly on mitotic activity, with CDKN2A loss considered the most common mechanism for cell cycle dysregulation. We investigated whether of gene is associated overall survival across pathologically genetically defined glioma subtypes. After adjustment IDH mutation, sex, age, deletion was strongly poorer astrocytomas but...

10.1097/nen.0000000000000188 article EN Journal of Neuropathology & Experimental Neurology 2015-04-08
Coming Soon ...